Cell-free Detection of GPCR Signaling in a Nanoscale System

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$1,192,925.00
Award Year:
2008
Program:
SBIR
Phase:
Phase II
Contract:
2R44GM072379-03
Award Id:
76274
Agency Tracking Number:
GM072379
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
INTEGRAL MOLECULAR, 3701 MARKET ST, STE 340, PHILADELPHIA, PA, 19104
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
034055645
Principal Investigator:
BENJAMIN DORANZ
(215) 966-6018
BDORANZ@INTEGRALMOLECULAR.COM
Business Contact:
() -
bdoranz@integralmolecular.com
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): G protein-coupled receptors (GPCRs) are one of the most important families of pharmaceutical targets. However, some of the most desirable types of GPCR drugs have also been some of the most difficult to discover. GPCRs are integral membrane proteins that are traditionally studied in live cells or cell membrane preparations, sources that limit the ability to purify and manipulate GPCR proteins. These limitations have hindered the discovery of drugs against many important GPCRs and drugs with pharmacologically-specific mechanisms of action. A novel method that aids in discovering new and improved GPCR drugs could have a major impact on human health. We have demonstrated the feasibility of a unique assay system for GPCR acti vation that offers the benefits of a cell-based system (relevant signaling pathways) without their drawbacks. Our strategy involves the use of a novel technology, the Lipoparticle that enables structurally-intact GPCRs to be purified away from cells and as sayed for activity. The Specific Aims of our proposal are: I. Test the LipoSignal assay for screening diverse GPCR activators and inhibitors II. Develop the LipoSignal assay to target pharmacologically distinguishable GPCR signaling mechanisms III. Format a LipoSignal Array to identify GPCR cross-reactivity and orphan GPCR-ligand pairs. PUBLIC HEALTH RELEVANCE: The product that results from this proposal will contribute to public health and the cure of human diseases by providing a novel approach for identifying better drugs and new ligands against GPCRs. The chemokines receptors, including CXCR4 and CCR5, are involved in cancer, inflammatory diseases, and HIV infection, and are a major focus of this proposal. However, our technology has broad applica tion to a diverse range of GPCRs, and also has the capability of being used to identify cell- and signaling pathway-specific GPCR drugs that are difficult to identify using conventional assays. As a result of this proposal, we expect to commercialize a pro duct that will lead directly to the development of new and improved GPCR drugs.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government